Beigene Ltd
HKEX:6160
Beigene Ltd
Research & Development
Beigene Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Beigene Ltd
HKEX:6160
|
Research & Development
-ÂĄ12.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
||
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-ÂĄ2.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Research & Development
-ÂĄ1.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Research & Development
-ÂĄ1.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Research & Development
-ÂĄ1B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
||
Imeik Technology Development Co Ltd
SZSE:300896
|
Research & Development
-ÂĄ232.4m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
Beigene Ltd
Glance View
BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.
See Also
What is Beigene Ltd's Research & Development?
Research & Development
-12.5B
CNY
Based on the financial report for Dec 31, 2023, Beigene Ltd's Research & Development amounts to -12.5B CNY.
What is Beigene Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-22%
Over the last year, the Research & Development growth was -15%. The average annual Research & Development growth rates for Beigene Ltd have been -13% over the past three years , -22% over the past five years .